You can buy or sell Catabasis and other stocks, options, ETFs, and crypto commission-free!
Catabasis Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of novel therapeutics. Its lead product candidate is edasalonexent, which is intended for the treatment of Duchenne muscular dystrophy. Read More The company was founded by Michael R. Jirousek, Jill C. Milne and Steven E. Shoelson on June 26, 2008 and is headquartered in Boston, MA. The listed name for CATB is Catabasis Pharmaceuticals, Inc. Common Stock.
52 Week High
52 Week Low
— per share
Expected Nov 5, Pre-Market